OptiBiotix partners US firm for large scale manufacturing of SweetBiotix products

SweetBiotix products

LONDON: OptiBiotix Health, a life sciences business, has entered into an agreement with a US company for the purpose of large scale manufacture and commercialisation of a number of SweetBiotix products, a news release said.

The agreement grants the US Company an exclusive worldwide license in return for it bearing the costs relating to product manufacturing, marketing, and all future costs relating to the commercialisation of a number of SweetBiotix products.

OptiBiotix will receive a modest six-figure payment from the Company on signing the agreement and at 12 monthly intervals until product launch.  Additional similar payments will be due on product launch plus royalties on all future product sales. 

Enhanced royalty payments will be made to OptiBiotix on sale of SweetBiotix products by the Company to 11 application/innovation partners with whom OptiBiotix has been in long term discussions regarding exploring the use of SweetBiotix products in dairy, cereal and beverage applications.

The US Company requires its identity and certain commercial terms of the agreement to remain confidential to protect its commercial launch plans.

Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce this agreement for SweetBiotix, a family of products based on the concept of creating a sweet fibre with a low glycaemic index which enhances the microbiome.  The agreement allows the US Company to invest in the large scale manufacture and commercialisation of a number of SweetBiotix products in return for upfront, annual and product launch milestone payments, plus royalties on all future product sales.

“With concerns over the amount of sugar and lack of fibre in consumer diets creating high levels of diabetes and obesity, this agreement brings closer the prospect of replacing ‘unhealthy’ sugars with healthy sweet fibres which contain no calories and improving microbiome diversity and the benefits of SweetBiotix technology to a global audience.”

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The current areas of focus for the business include obesity, cardiovascular health, and diabetes.


About the author

Leave a Reply

Your email address will not be published. Required fields are marked *